FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3143409872> ?p ?o ?g. }

• W3143409872 endingPage "780" @default.
• W3143409872 startingPage "768" @default.
• W3143409872 abstract "The aim of this study was to explore the early versus late benefits and risks of dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial.Patients with atrial fibrillation who undergo percutaneous coronary intervention are at increased risk for both bleeding and thrombotic events.A total of 2,725 patients with atrial fibrillation underwent percutaneous coronary intervention and were randomized to receive dabigatran 110 mg, or dabigatran 150 mg plus a P2Y12 inhibitor (and no aspirin), or warfarin plus a P2Y12 inhibitor plus aspirin. Landmark analysis was performed at 30 and 90 days.There was a consistent and large reduction in major or clinically relevant nonmajor bleeding in patients randomized to dual therapy during the first 30 days (110 mg: hazard ratio [HR]: 0.45; 95% confidence interval [CI]: 0.31 to 0.66; p < 0.0001; 150 mg: HR: 0.46; 95% CI: 0.30 to 0.72; p = 0.0006) compared with warfarin triple therapy. There was early net clinical benefit in both dabigatran groups versus warfarin (110 mg: HR: 0.65; 95% CI: 0.47 to 0.88; p = 0.0062; 150 mg: HR: 0.54; 95% CI: 0.37 to 0.79; p = 0.0015), due to larger reductions in bleeding than increased thrombotic events for dabigatran 110 mg and bleeding reduction without increased thrombotic risk for dabigatran 150 mg dual therapy versus warfarin triple therapy. After the removal of aspirin in the warfarin group, bleeding remained lower with dabigatran 110 mg and was similar with dabigatran 150 mg versus warfarin.In RE-DUAL PCI, in which patients in the dual-therapy arms were treated with aspirin for an average of only 1.6 days, there was early net clinical benefit with both doses of dabigatran dual therapy, without an increase in thrombotic events with dabigatran 150 mg. This could be helpful in the subset of patients with elevated risk for both bleeding and thrombotic events." @default.
• W3143409872 created "2021-04-13" @default.
• W3143409872 creator A5009430890 @default.
• W3143409872 creator A5010571732 @default.
• W3143409872 creator A5012209049 @default.
• W3143409872 creator A5013878625 @default.
• W3143409872 creator A5025592036 @default.
• W3143409872 creator A5026602252 @default.
• W3143409872 creator A5037551685 @default.
• W3143409872 creator A5038405190 @default.
• W3143409872 creator A5056522927 @default.
• W3143409872 creator A5057062433 @default.
• W3143409872 creator A5063802183 @default.
• W3143409872 creator A5078418468 @default.
• W3143409872 creator A5078909594 @default.
• W3143409872 creator A5081852908 @default.
• W3143409872 creator A5085128848 @default.
• W3143409872 creator A5085798844 @default.
• W3143409872 date "2021-04-01" @default.
• W3143409872 modified "2023-10-10" @default.
• W3143409872 title "Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial" @default.
• W3143409872 cites W1812460259 @default.
• W3143409872 cites W1976469399 @default.
• W3143409872 cites W1999468381 @default.
• W3143409872 cites W2004413589 @default.
• W3143409872 cites W2022506351 @default.
• W3143409872 cites W2078973349 @default.
• W3143409872 cites W2090120321 @default.
• W3143409872 cites W2096246254 @default.
• W3143409872 cites W2097854437 @default.
• W3143409872 cites W2105345588 @default.
• W3143409872 cites W2127123808 @default.
• W3143409872 cites W2135082975 @default.
• W3143409872 cites W2136489990 @default.
• W3143409872 cites W2138740885 @default.
• W3143409872 cites W2147018083 @default.
• W3143409872 cites W2159193915 @default.
• W3143409872 cites W2159337926 @default.
• W3143409872 cites W2159370853 @default.
• W3143409872 cites W2162508946 @default.
• W3143409872 cites W2165626532 @default.
• W3143409872 cites W2178192308 @default.
• W3143409872 cites W2508853990 @default.
• W3143409872 cites W2547650521 @default.
• W3143409872 cites W2551153034 @default.
• W3143409872 cites W2556417520 @default.
• W3143409872 cites W2613079353 @default.
• W3143409872 cites W2749380187 @default.
• W3143409872 cites W2749929702 @default.
• W3143409872 cites W2802512131 @default.
• W3143409872 cites W2887586296 @default.
• W3143409872 cites W2894210929 @default.
• W3143409872 cites W2917582759 @default.
• W3143409872 cites W2921724943 @default.
• W3143409872 cites W2949986921 @default.
• W3143409872 cites W2953934063 @default.
• W3143409872 cites W2972299172 @default.
• W3143409872 cites W3013012074 @default.
• W3143409872 cites W3025095208 @default.
• W3143409872 cites W3082188176 @default.
• W3143409872 cites W3106731792 @default.
• W3143409872 cites W3126662497 @default.
• W3143409872 cites W4239330499 @default.
• W3143409872 cites W4245708227 @default.
• W3143409872 doi "https://doi.org/10.1016/j.jcin.2021.02.022" @default.
• W3143409872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33826497" @default.
• W3143409872 hasPublicationYear "2021" @default.
• W3143409872 type Work @default.
• W3143409872 sameAs 3143409872 @default.
• W3143409872 citedByCount "4" @default.
• W3143409872 countsByYear W31434098722021 @default.
• W3143409872 countsByYear W31434098722022 @default.
• W3143409872 crossrefType "journal-article" @default.
• W3143409872 hasAuthorship W3143409872A5009430890 @default.
• W3143409872 hasAuthorship W3143409872A5010571732 @default.
• W3143409872 hasAuthorship W3143409872A5012209049 @default.
• W3143409872 hasAuthorship W3143409872A5013878625 @default.
• W3143409872 hasAuthorship W3143409872A5025592036 @default.
• W3143409872 hasAuthorship W3143409872A5026602252 @default.
• W3143409872 hasAuthorship W3143409872A5037551685 @default.
• W3143409872 hasAuthorship W3143409872A5038405190 @default.
• W3143409872 hasAuthorship W3143409872A5056522927 @default.
• W3143409872 hasAuthorship W3143409872A5057062433 @default.
• W3143409872 hasAuthorship W3143409872A5063802183 @default.
• W3143409872 hasAuthorship W3143409872A5078418468 @default.
• W3143409872 hasAuthorship W3143409872A5078909594 @default.
• W3143409872 hasAuthorship W3143409872A5081852908 @default.
• W3143409872 hasAuthorship W3143409872A5085128848 @default.
• W3143409872 hasAuthorship W3143409872A5085798844 @default.
• W3143409872 hasBestOaLocation W31434098721 @default.
• W3143409872 hasConcept C126322002 @default.
• W3143409872 hasConcept C164705383 @default.
• W3143409872 hasConcept C168563851 @default.
• W3143409872 hasConcept C207103383 @default.
• W3143409872 hasConcept C2776301958 @default.
• W3143409872 hasConcept C2777628954 @default.
• W3143409872 hasConcept C2777849778 @default.
• W3143409872 hasConcept C2778810321 @default.

• next